Oncology and Cancer Immunology Research
Our commitment to innovation in oncology research has resulted in the launch of two products for the treatment of non-small cell lung cancer. Our research strategy has two major focus areas: cancer cell-directed therapies and immune cell-directed therapies.
Our experience
Our oncology pipeline encompasses more than ten clinical stage assets. These are being developed in various cancers and tumor types, including multiple new biological entities and new chemical entities that are currently being investigated in studies involving more than 20,500 patients. We are poised for the next wave of innovation with clinical phase projects involving oncolytic viruses, cancer vaccines and T-cell engagers.
Located in Austria and the USA, our dedicated Oncology research centers are the hubs for our cancer R&D activities where our scientists, working together with our innovation partners, have the ambition to identify and translate the most promising scientific breakthroughs into clinical applications for patients across a wide range of cancers.
Our research focus
Research in oncology and cancer immunology has two major focus areas.
Cancer cell-directed therapies including:
- Growth signaling
- Regulation of apoptosis
- Epigenetic regulation
- Regulation of protein homeostasis.
Immune cell-directed therapies
- Priming of tumor-specific T-cells
- Cancer vaccines
- Immune cell re-activation: Checkpoint control, NK-cell activation
- Immune cell re-direction: T-cell engager approaches.